{
    "1": {
        "question": "What was the main finding from 3 cycles of the fasting-mimicking diet (FMD) regarding biological age?",
        "options": {
            "A": "Increased biological age by 2.5 years",
            "B": "Decreased biological age by 2.5 years",
            "C": "Had no effect on biological age",
            "D": "Increased chronological age by 2.5 years",
            "E": "Decreased chronological age by 2.5 years",
            "F": "I don't know"
        }
    },
    "2": {
        "question": "How did the FMD affect insulin resistance in the study participants?",
        "options": {
            "A": "Increased insulin resistance",
            "B": "Decreased insulin resistance",
            "C": "Had no effect on insulin resistance",
            "D": "Only affected insulin resistance in mice",
            "E": "Increased insulin levels but decreased glucose levels",
            "F": "I don't know"
        }
    },
    "3": {
        "question": "What change was observed in the lymphoid to myeloid ratio after 3 FMD cycles?",
        "options": {
            "A": "Decreased",
            "B": "Increased",
            "C": "Remained unchanged",
            "D": "Shifted towards myeloid lineage",
            "E": "Shifted towards lymphoid lineage only in mice",
            "F": "I don't know"
        }
    },
    "4": {
        "question": "In the study, how was the hepatic fat fraction affected by FMD in overweight participants?",
        "options": {
            "A": "Increased significantly",
            "B": "Decreased slightly",
            "C": "Increased slightly",
            "D": "Decreased significantly",
            "E": "Remained the same",
            "F": "I don't know"
        }
    },
    "5": {
        "question": "What was the primary method used to assess changes in hepatic fat during the study?",
        "options": {
            "A": "Blood test",
            "B": "Ultrasound",
            "C": "Magnetic Resonance Imaging (MRI)",
            "D": "X-ray",
            "E": "CT Scan",
            "F": "I don't know"
        }
    },
    "6": {
        "question": "What percentage of study participants in trial NCT02158897 showed an increase in biological age after FMD cycles?",
        "options": {
            "A": "10%",
            "B": "21%",
            "C": "30.7%",
            "D": "40%",
            "E": "50%",
            "F": "I don't know"
        }
    },
    "7": {
        "question": "Which cardiovascular risk factors were reduced by the FMD according to the study?",
        "options": {
            "A": "Total cholesterol, blood pressure, and CRP levels",
            "B": "Only insulin and blood sugar levels",
            "C": "Body weight, BMI, LDL cholesterol",
            "D": "Only HDL cholesterol and triglycerides",
            "E": "Fasting glucose and IGF-1",
            "F": "I don't know"
        }
    },
    "8": {
        "question": "How did the FMD study ensure participants returned to a normal diet after each cycle?",
        "options": {
            "A": "Participants were not allowed to eat",
            "B": "Participants consumed a fixed diet provided by the study",
            "C": "Participants were advised to resume their normal diet",
            "D": "Participants were given specific meals provided for the transition",
            "E": "Participants were monitored at home for compliance",
            "F": "I don't know"
        }
    },
    "9": {
        "question": "What was the effect of the FMD on participant weight loss compared to biological age changes?",
        "options": {
            "A": "Weight loss had no effect on changes in biological age",
            "B": "Weight loss caused a significant increase in biological age",
            "C": "Changes in biological age were associated with BMI changes",
            "D": "Weight loss explained all changes in biological age",
            "E": "Greater weight loss led to a higher decrease in biological age",
            "F": "I don't know"
        }
    },
    "10": {
        "question": "How was the lymphoid/myeloid ratio affected in study participants over 40 years old?",
        "options": {
            "A": "It decreased significantly",
            "B": "It increased significantly",
            "C": "It stayed the same",
            "D": "Only decreased in participants under 30",
            "E": "Only changed in participants over 50",
            "F": "I don't know"
        }
    },
    "11": {
        "question": "How did FMD cycles affect the median life expectancy prediction for participants?",
        "options": {
            "A": "Decreased by 5 years",
            "B": "Increased by 5 years",
            "C": "Increased by one year",
            "D": "Remained the same",
            "E": "Reduced predictability due to variability",
            "F": "I don't know"
        }
    },
    "12": {
        "question": "What was used as a proxy to assess the impact of FMD cycles on health or lifespan?",
        "options": {
            "A": "Weight loss",
            "B": "Blood pressure",
            "C": "Biological age estimates",
            "D": "IGF-1 levels",
            "E": "Lifespan of mice",
            "F": "I don't know"
        }
    },
    "13": {
        "question": "What was the purpose of measuring the Homeostatic Model Assessment (HOMA-IR) in the study?",
        "options": {
            "A": "To calculate participants' BMI",
            "B": "To measure insulin resistance",
            "C": "To measure glucose levels only",
            "D": "To determine liver function",
            "E": "To assess cholesterol levels",
            "F": "I don't know"
        }
    },
    "14": {
        "question": "Which demographic characteristic was more balanced in the MRI volunteer group compared to non-MRI participants?",
        "options": {
            "A": "Weight",
            "B": "Age",
            "C": "Gender",
            "D": "Ethnicity",
            "E": "Height",
            "F": "I don't know"
        }
    },
    "15": {
        "question": "What significant change was observed in participants with a BMI > 25 after FMD cycles?",
        "options": {
            "A": "Increase in liver fat",
            "B": "Decrease in pancreatic fat",
            "C": "Increase in visceral adipose tissue",
            "D": "Decrease in subcutaneous adipose tissue",
            "E": "Decrease in visceral adipose tissue",
            "F": "I don't know"
        }
    },
    "16": {
        "question": "Which cellular process was activated by the periodic FMD according to preclinical studies?",
        "options": {
            "A": "Glycolysis",
            "B": "Apoptosis",
            "C": "Autophagy",
            "D": "Telomere shortening",
            "E": "Lipogenesis",
            "F": "I don't know"
        }
    },
    "17": {
        "question": "How is the fasting-mimicking diet (FMD) structured in terms of duration?",
        "options": {
            "A": "1 day each week",
            "B": "3 consecutive days per month",
            "C": "5 consecutive days per month",
            "D": "7 consecutive days per month",
            "E": "Every alternate day for a week",
            "F": "I don't know"
        }
    },
    "18": {
        "question": "What did pooling samples from the two FMD trials show about biological age?",
        "options": {
            "A": "No change in biological age",
            "B": "Decrease by 2.6 years",
            "C": "Increase by 2.6 years",
            "D": "Fluctuating results with no clear trend",
            "E": "Significant increase in biological age only in the second trial",
            "F": "I don't know"
        }
    },
    "19": {
        "question": "Which marker showed a high correlation with changes in biological age and was associated with reduced systemic inflammation?",
        "options": {
            "A": "Systolic blood pressure",
            "B": "Albumin",
            "C": "Hba1c",
            "D": "Blood glucose",
            "E": "Serum creatinine",
            "F": "I don't know"
        }
    },
    "20": {
        "question": "What did the study use to simulate the effects of annual FMD cycles from age 20 to 70?",
        "options": {
            "A": "Clinical trial data fitted to NHANES IV population",
            "B": "Mouse model simulations",
            "C": "Controlled laboratory experiments",
            "D": "Longitudinal observational studies",
            "E": "Dietary recall forms",
            "F": "I don't know"
        }
    },
    "21": {
        "question": "What outcome was assessed using a Kaplan-Meier survival curve in the study?",
        "options": {
            "A": "Heart disease incidence",
            "B": "Expected maximum lifespan",
            "C": "Predicted median life expectancy",
            "D": "Liver enzyme levels",
            "E": "Cancer probability",
            "F": "I don't know"
        }
    },
    "22": {
        "question": "According to the article, when does the FMD show the largest decline in biological age?",
        "options": {
            "A": "When started at age 60",
            "B": "During the first 5 cycles",
            "C": "Upon completion of three cycles",
            "D": "During the first cycle specifically",
            "E": "In participants with accelerated aging rates",
            "F": "I don't know"
        }
    },
    "23": {
        "question": "What risk factor was associated with participants benefitting most from biological age reduction following FMD?",
        "options": {
            "A": "BMI > 25",
            "B": "Normal blood pressure",
            "C": "High dietary sugar intake",
            "D": "Lack of exercise",
            "E": "Increased sodium intake",
            "F": "I don't know"
        }
    },
    "24": {
        "question": "What prediction does the study make regarding FMD's effect on the prevalence of chronic age-related diseases over 20 years?",
        "options": {
            "A": "Increase by 10%",
            "B": "No change at all",
            "C": "Minimal effect compared to normal diet",
            "D": "Reduction in diabetes, cancer, and heart disease risks",
            "E": "Increase in metabolic syndrome incidence",
            "F": "I don't know"
        }
    },
    "25": {
        "question": "How were liver fat and pancreatic fat differentially affected by the FMD?",
        "options": {
            "A": "Both increased significantly",
            "B": "Liver fat decreased, pancreatic fat remained unchanged",
            "C": "Liver fat and pancreatic fat both decreased",
            "D": "Pancreatic fat decreased, liver fat remained unchanged",
            "E": "Both remained unchanged",
            "F": "I don't know"
        }
    },
    "26": {
        "question": "What is the main goal of using biological age as a marker in FMD studies?",
        "options": {
            "A": "To determine chronological age changes",
            "B": "To provide more accurate health risk assessments",
            "C": "To measure skin aging",
            "D": "To compare aging rates between species",
            "E": "To estimate genetic makeup differences",
            "F": "I don't know"
        }
    },
    "27": {
        "question": "What was the composition of the FMD over the 5-day period in terms of macronutrients?",
        "options": {
            "A": "High protein, low carbohydrate, low fat",
            "B": "Equal proportions of proteins, fats, and carbohydrates",
            "C": "Low protein, moderate carbohydrate, high fat",
            "D": "Low protein, low fat, high carbohydrate",
            "E": "Low protein, moderate carbohydrate, moderate fat",
            "F": "I don't know"
        }
    },
    "28": {
        "question": "What percentage of study participants in trial NCT04150159 exhibited increased biological ages following 3 FMD cycles?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "21%",
            "E": "31%",
            "F": "I don't know"
        }
    },
    "29": {
        "question": "Which group experienced a 50% reduction in liver fat percentage post FMD cycles?",
        "options": {
            "A": "All study participants",
            "B": "Participants with normal liver function",
            "C": "Participants affected by overweight with over 5% HFF",
            "D": "Participants from the control group",
            "E": "Participants with pancreatic issues",
            "F": "I don't know"
        }
    },
    "30": {
        "question": "What was a significant limitation of the simulation assessing annual FMD cycles from age 50?",
        "options": {
            "A": "Inclusion of participants up to age 80",
            "B": "Assumption that FMD effects are linear",
            "C": "Exclusion of cardiometabolic data",
            "D": "No consideration of compliance or dropout",
            "E": "Use of single cohort across trials without bias",
            "F": "I don't know"
        }
    },
    "31": {
        "question": "What was the trend observed with systolic blood pressure and CRP levels in non-responders at baseline?",
        "options": {
            "A": "They were higher compared to responders",
            "B": "They did not correlate with response status",
            "C": "They were inversely correlated with response status",
            "D": "Only CRP levels were elevated",
            "E": "Only systolic blood pressure was elevated",
            "F": "I don't know"
        }
    },
    "32": {
        "question": "How long was the duration of the follow-up after the final FMD cycle in the trial?",
        "options": {
            "A": "1 month",
            "B": "2 months",
            "C": "3 months",
            "D": "4 months",
            "E": "6 months",
            "F": "I don't know"
        }
    },
    "33": {
        "question": "What was the observed weight adjustment in trial NCT04150159 in relation to biological age?",
        "options": {
            "A": "Biological age increased with weight loss",
            "B": "Biological age was unaffected by weight loss",
            "C": "Weight loss explained all decrease in biological age",
            "D": "Greater weight loss associated with greater age increase",
            "E": "Weight gain resulted in reduced biological age",
            "F": "I don't know"
        }
    },
    "34": {
        "question": "What type of design was used in trial NCT02158897?",
        "options": {
            "A": "Parallel-group design",
            "B": "Cross-over randomized design",
            "C": "Observational design",
            "D": "Retrospective design",
            "E": "Open-label design",
            "F": "I don't know"
        }
    },
    "35": {
        "question": "What effect did the FMD have on albumin levels and its correlation with biological age change?",
        "options": {
            "A": "Reduced albumin correlated with biological age increase",
            "B": "Increased albumin correlated with biological age decrease",
            "C": "No correlation observed",
            "D": "Albumin levels were unaffected",
            "E": "Albumin increased without correlation to age change",
            "F": "I don't know"
        }
    },
    "36": {
        "question": "What notable change occurred in high-density lipoprotein (HDL) cholesterol levels in the study?",
        "options": {
            "A": "Increase observed in arm 1",
            "B": "Decrease observed in arm 2",
            "C": "No change in both arms",
            "D": "Significant decrease in both arms",
            "E": "Increase in triglyceride-rich lipoproteins",
            "F": "I don't know"
        }
    },
    "37": {
        "question": "What were the baseline characteristics used to assign study participants to being non-responders?",
        "options": {
            "A": "High baseline BMI",
            "B": "Elevated cholesterol",
            "C": "Elevated systolic blood pressure and CRP",
            "D": "Normal Hba1c",
            "E": "Elevated alkaline phosphatase",
            "F": "I don't know"
        }
    },
    "38": {
        "question": "With respect to what parameter did the FMD not lead to a significant change in study participants?",
        "options": {
            "A": "Liver fat percentages",
            "B": "Body weight reduction",
            "C": "Pancreatic fat fraction",
            "D": "Serum glucose",
            "E": "HOMA-IR",
            "F": "I don't know"
        }
    },
    "39": {
        "question": "What effect did the FMD have on the incidence of cancer in rodent studies?",
        "options": {
            "A": "Increased incidence of cancer",
            "B": "Decreased incidence of cancer",
            "C": "No effect on cancer incidence",
            "D": "Results varied with rodent type",
            "E": "Cancer incidence was unaffected",
            "F": "I don't know"
        }
    },
    "40": {
        "question": "What was the main focus of the second trial, NCT04150159?",
        "options": {
            "A": "Effects of FMD on mice longevity",
            "B": "Comparison of FMD and calorie restriction",
            "C": "Using FMD to reduce cardiometabolic risk factors",
            "D": "Testing FMD for reducing liver disease",
            "E": "Evaluation of FMD on immune function",
            "F": "I don't know"
        }
    },
    "41": {
        "question": "Which measure indicated deviation towards younger immune phenotype after FMD?",
        "options": {
            "A": "Decrease in IGF-1",
            "B": "Improved insulin sensitivity",
            "C": "Enhanced lymphoid to myeloid ratio",
            "D": "Reduced glucose levels only",
            "E": "Diastolic blood pressure decrease",
            "F": "I don't know"
        }
    },
    "42": {
        "question": "What was the source of changes in biomarkers correlating with biological age improvement?",
        "options": {
            "A": "Dietary shifts alone",
            "B": "Exercise routines",
            "C": "General rejuvenating effects in cells and tissue",
            "D": "Increase in lean body mass",
            "E": "Increased sleep duration",
            "F": "I don't know"
        }
    },
    "43": {
        "question": "Which fasting parameter did the FMD specifically target for reduction?",
        "options": {
            "A": "Total food abstinence",
            "B": "Water-only fasting",
            "C": "Five-day calorie restriction",
            "D": "Regular caloric intake with increased carbohydrates",
            "E": "Complete protein restriction",
            "F": "I don't know"
        }
    },
    "44": {
        "question": "What was the average predicted life expectancy increase after 3 FMD cycles?",
        "options": {
            "A": "From 82.93 to 84.73 years",
            "B": "From 82.93 to 83.73 years",
            "C": "From 81.5 to 82 years",
            "D": "From 80 to 83 years",
            "E": "From 75 to 80 years",
            "F": "I don't know"
        }
    },
    "45": {
        "question": "What was the significance of the changes in Hemoglobin A1c (HbA1c) in pre-diabetic study participants?",
        "options": {
            "A": "Remained unchanged",
            "B": "Increased after intervention",
            "C": "Decreased significantly post-intervention",
            "D": "Showed no pattern of change",
            "E": "Correlated with weight gain",
            "F": "I don't know"
        }
    },
    "46": {
        "question": "By how much did the predicted maximum life expectancy differ between FMD and no FMD from age 50?",
        "options": {
            "A": "12 years",
            "B": "5 years",
            "C": "7 years",
            "D": "10 years",
            "E": "2 years",
            "F": "I don't know"
        }
    },
    "47": {
        "question": "Which aspect did the study not account for in its long-term simulation predictions?",
        "options": {
            "A": "Change in life expectancy",
            "B": "Participant compliance",
            "C": "Mortality rate estimation",
            "D": "Dropout rates",
            "E": "FMD effect weakening over time",
            "F": "I don't know"
        }
    },
    "48": {
        "question": "What changes were observed in glucose tolerance in individuals post FMD cycles?",
        "options": {
            "A": "Reduced glucose tolerance",
            "B": "Marginal improvement",
            "C": "Restored to normal range in pre-diabetics",
            "D": "No effect at all",
            "E": "Inconsistently reduced",
            "F": "I don't know"
        }
    },
    "49": {
        "question": "What change was observed in baseline biological age using the NHANES method after 3 FMD cycles?",
        "options": {
            "A": "Increase of 3 years",
            "B": "Decrease of 2.5 years",
            "C": "Increase of 1.5 years",
            "D": "Decrease of 1.5 years",
            "E": "Minimal change with large variance",
            "F": "I don't know"
        }
    },
    "50": {
        "question": "Which phenomenon describes the decline in immune function with age?",
        "options": {
            "A": "Metabolic syndrome",
            "B": "Cancer immuno-editing",
            "C": "Immunosenescence",
            "D": "Antibody-dependent enhancement",
            "E": "Chronic immunosuppression",
            "F": "I don't know"
        }
    }
}